Jazz Pharmaceuticals

A recent report from the U.S. Federal Trade Commission (FTC) has brought attention to the substantial influence of pharmacy benefit managers (PBMs) on drug pricing due to market consolidation. This situation raises important questions about the future of the cannabis industry, particularly in the...

German Researchers Find CBD Potential For Inflammation  A new study has made strides in understanding the anti-inflammatory properties of cannabinoids, with a particular focus on CBD. Cannabis has long been recognized for its pain-relieving and muscle-relaxing qualities, but the...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results for the second quarter of 2023, along with its outlook for the remainder of the year. Financial Highlights GAAP net income for Q2 2023 stood at $104.4 million, reflecting an increase from $34.7 million in the same period...

Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical trials. Spasticity is characterized by increased muscle stiffness and spasms, which can be...

Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Apotex, Alkem and several other generic drugmakers alleging patent infringement on the cannabis-derived therapy...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance. "Our execution across our business continues to chart a clear path to delivering on Vision 2025. We have...

Shares of Celator Pharmaceuticals Inc (NASDAQ: CPXX) surged higher by more than 70 percent early Tuesday morning after the company has agreed to be acquired by Jazz Pharmaceuticals plc (NASDAQ: JAZZ) for approximately $1.5 billion, or $30.25 per share. Celator's stock closed for trading at...

U.S. stocks rose as geopolitical events took a back seat and investors found positives in housing and consumer price index data released Tuesday. The markets followed the lead of Apple which closed at an all-time split-adjusted high of $100.53. Earnings from Home Depot and TJX Companies also...

U.S. stocks were mostly higher on Thursday as both the S&P 500 index and Nasdaq index recorded a fourth straight winning session in a relatively slow news day that was heavy on earnings. The Dow Jones rose as much as 35 points and falling as much as 56 as earnings from Dow listed companies...

U.S. stocks rose in the final day of the first quarter as the Fed's boss Janet Yellen said there is still room for the central bank to further boost the economy. Yellen, speaking in Chicago today, said the scars from the Great Recession remain, and reaching our goals will take time." Yellen...

U.S. stocks finished the week on a positive note despite a sell-off in the afternoon. One possible reason for the sell-off is that investors are adjusting their portfolios for the end of the quarter on Monday. Major indices rallied off the opening bell with the Dow Jones Industrial Average...

U.S. stocks were mixed as investors continue to follow the standoff in Ukraine and digested February's jobs report which indicated that harsh winter weather could be the culprit behind weakness seen in recent economic data reports. The S&P 500 trading at new all time highs at 1,883.57 but...

Major indices received a boost in Friday's trading activity following a better than expected third quarter GDP. The surprising economic data is yet another key data that may suggests that the economy is healthy enough and could handle the Fed's recent decision to taper its bond buying program....

U.S stocks started off the week on a positive note with triple digit point gains for the Dow following one of the worst weeks in recent memory. Tuesday is an important day for the markets as the Fed begins its policy meeting which will last until Wednesday. After weeks of anticipating when (or...